Searched for
AFFORDABLE GENERIC MEDICINES
Centre proposes easier norms for faster drug rolloutIndia's government plans to streamline drug approval processes for domestic use. Applicants can now start studies after intimating the drug...- Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely sellerBiocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 cr...
- Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block dealActive Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development...
- Sun Pharma to extend MFN pricing to US state Medicaid programmesSun Pharma ranks second in US dermatology by prescriptions, with key brands including Ilumya for plaque psoriasis and Winlevi for acne. Rec...
- Brazil, South Africa, India Key global south partners: Mauro VieiraBrazilian Foreign Minister Mauro Vieira has described Brazil, South Africa and India as major democratic partners of the Global South, stre...
- NFO Insight: Invesco India Pharma and Healthcare Fund opens for subscription. Right time to invest in pharma funds?Invesco India has unveiled an innovative pharma and healthcare fund tailored for investors seeking opportunities in India's burgeoning heal...
- Indian pharma has little reason to fear TrumpUS tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially...
- Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjectorBiocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two stren...
- Mark Cuban’s ‘beyond incredible’ gesture wins hearts after heart transplant survivor faces $1,000 bill for vital medicineAfter undergoing a heart transplant, a survivor encountered steep increases in medication costs, initially losing her insurance coverage on...
- Swadeshi 1.0 vs. Made in India 2.0: How India turned a 1905 boycott into a 2026 business strategyIndependence Day 2026: From the Swadeshi movement to Atmanirbhar Bharat. Early Swadeshi movements fostered indigenous industries against im...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- Dr Reddy's Laboratories launches generic Sugammadex injection in the United StatesDr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effec...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- US tariff proposal wake-up call for Indian pharma to diversify, innovate: ExpertsUS pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...
- Tariffs alone will not produce sustainable generic medicine in US: IPAThe Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair...
- Generic drugmaker Sandoz to engage with US after Trump tariff threatUS President Donald Trump threatened steep tariffs on generic drugmakers. He stated medicines must be manufactured locally or face signific...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
Load More
